安罗替尼三线治疗小细胞肺癌的临床安全性和有效性观察

Observation on clinical safety and efficacy of anlotinib in third-line treatment of small cell lung cancer

目的 分析安罗替尼三线治疗小细胞肺癌的临床安全性和有效性。方法 34例小细胞肺癌患者,均接受安罗替尼三线治疗。比较患者治疗前后的神经元特异性烯醇化酶(NSE)水平、卡氏功能状态评定量表(KPS)评分、体重,分析患者的临床治疗效果、生存情况以及治疗期间的不良反应发生情况。结果 患者治疗后NSE(23.87±3.14)μg/L显著低于治疗前的(37.28±4.23)μg/L,差异有统计学意义(P<0.05);患者治疗后KPS评分为(65.18±5.51)分、体重为(54.29±4.20)kg,与治疗前的(66.38±5.22)分、(55.11±4.98)kg比较,差异无统计学意义(P>0.05)。34例患者经治疗后,客观有效率(ORR)为5.88%(2/34),疾病控制率(DCR)为70.59%(24/34)。经随访,患者的无进展生存期(PFS)为3.37~4.68个月,中位PFS为4.36个月;总生存期(OS)为6.40~8.42个月,中位OS为7.33个月。34例患者治疗期间出现不同程度的蛋白尿、腹泻、浑身乏力、高血压、皮疹、肝功能异常、贫血等不良反应,其中,分级在Ⅲ~Ⅳ级之间的有1例腹泻、1例贫血和2例高血压,发生率为11.76%。结论 安罗替尼三线治疗小细胞肺癌效果良好,且不良反应发生率低,安全性佳,可以有效延长患者的生存时间,值得临床推广应用。

Objective To analyze the clinical safety and efficacy of anlotinib in third-line treatment of small cell lung cancer.Methods All 34 patients with small cell lung cancer received anlotinib as thirdline treatment.The neuron-specific enolase(NSE)level,Karnofsky performance status(KPS)score and body weight were compared before and after treatment,and the clinical therapeutic effect,survival and the occurrence of adverse reactions during treatment were analyzed.Results NSE was(23.87±3.14)μg/L after treatment,which was significantly lower than that of(37.28±4.23)μg/L before treatment,and the difference was statistically significant(P<0.05).After treatment,KPS score and body weight of the patients were(65.18±5.51)points and(54.29±4.20)kg,which were not statistically significant compared with those of(66.38±5.22)points and(55.11±4.98)kg before treatment(P>0.05).After treatment,the objective effective rate(ORR)was 5.88%(2/34)and disease control rate(DCR)was 70.59%(24/34).After follow-up,the patients'progression-free survival(PFS)was 3.37-4.68 months,the median PFS was 4.36 months,the overall survival(OS)was 6.40-8.42 months,and the median OS was 7.33 months.34 patients showed different degrees of albuminuria,diarrhea,fatigue,hypertension,rash,abnormal liver function,anemia and other adverse reactions during treatment.Among them,there were 1 case of diarrhea,1 case of anemia and 2 cases of hypertension graded between gradeⅢandⅣwith an incidence of 11.76%.Conclusion Anlotinib is effective in third-line treatment of small cell lung cancer with low incidence of adverse reactions and high safety,which can effectively prolong the survival time of patients and is worthy of clinical promotion and application.